Lowest Price Guaranteed From USD 4,799
Companies Covered
767
Pages
525
View Count
41796
In most of the cases, hit generation constitutes the majority of the R&D expenditure, leading to around 40% - 50% of the total cost, thus it is expected to hold the majority of the share of the antibody discovery services market.
-- President, US-based small sized company
The global antibody discovery services and platforms market size is estimated to be worth over $1.6 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 12.0% during the forecast period. The usual drug development process, beginning from discovery to commercialization of a clinically validated product spans around 10-15 years and requires investments of over $2 billion. However, despite the extensive efforts and investments, over 90% of the drug candidates fail in clinical trials. In order to streamline the drug development processes, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical players are increasingly outsourcing various aspects of their discovery-stage operations to specialized contract research organizations (CROs). By leveraging the capabilities of such antibody CRO, companies engaged in the antibody discovery market can optimize internal resource utilization and cost saving. Such strategic collaborations allow antibody discovery companies to tap into a global network of scientific talent, which leads to the enhancement of the overall efficiency and success rate of bringing novel antibody-based therapeutics to the market.
Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3®, in 1986, such antibodies have evolved into a versatile class of biopharmaceuticals, undergoing significant advancements in engineering, diversification of formats, and innovative discovery methods. Currently, more than 160 monoclonal antibodies have been approved by the various regulatory agencies around the world to be used in humans for the treatment of various diseases, including cancer, chronic inflammatory diseases, infectious diseases and cardiovascular diseases. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order of their approval date) ELREXFIO™ (August 2023), TALVEY™ (August 2023), Rystiggo® (June 2023), COLUMVI® (June 2023) and EPKINLY™ (May 2023). Owing to the complexities associated with the discovery of such monoclonal antibodies, many firms are opting to license and utilize specialized antibody discovery platforms and technologies. Further, given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for antibody discovery services and platforms is likely to increase at a significant growth rate in the foreseen future.
![]() |
![]() |
![]() |
The Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities within the antibody drug discovery services and platforms market during the forecast period. The market report highlights the efforts of the various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug discovery services and platforms market are briefly discussed below.
Outsourcing has been a strategic deployment of the pharmaceutical industry, for the past several decades, where companies delegate their various tasks to external vendors, in order to improve innovation and efficiency of their candidates. The contract research and manufacturing organizations accelerate the development timelines and ensure compliance with stringent regulations through their expertise. These organizations offer risk sharing and transfer and enhance adaptability to market growth. The growing interest in outsourcing of biopharmaceutical operations can be attributed to the need for rapid market access and the rising development costs. As pharmaceutical companies continue to embrace this trend, outsourcing is expected to continue to evolve the industry's landscape, optimizing operations and driving progress in therapeutic innovations.
Recent advancements in biotechnology, increasing demand for targeted therapies, ever-increasing prevalence of chronic diseases, increase in R&D expenditure in pharma and growing trend for outsourcing antibody discovery are some of the key drivers of the antibody drug discovery services and antibody discovery platforms market growth. In addition, the increasing number of collaborations between academic institutions and antibody discovery companies engaged in this industry contributes to the market growth. It is interesting to note that recently, in May 2023, Nona Biosciences signed an agreement with ModeX Therapeutics in order to integrate Harbour Mice® technology into the latter’s MSTAR platform for the discovery of improved treatment options.
Owing to the increase in applications of antibody drug discovery services and platforms, the industry has garnered significant interest from investors, which has resulted in a strong spur in investment activity in this market. For instance, in January 2023, IASO Biotherapeutics USD 75 million in a venture series C round. Further, it is worth highlighting that, in the past two years, four antibody discovery companies (Apexigen, Biocytogen, Shandong Boan Biotechnology and Twist Bioscience) have collectively raised over USD 375 million through initial public offerings. The funds raised by the companies operating in antibody discovery market will continue to advance the development of next generation antibody discovery platforms, which will support the development of novel antibody-based therapeutics driving the market growth over the forecast period.
Furthermore, several companies are entering into mergers and acquisitions to expand the service offerings in the antibody discovery market. In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary. The company acquired Abveris, an antibody discovery CRO in 2022 to gain hold of its single cell screening and hybridoma approach.
Licensing of antibody discovery platforms enables the companies to access innovative tools and methods for developing therapeutic antibodies, allowing firms to leverage specialized expertise and expand their R&D capabilities by avoiding the spend on the technology. Recent trends highlight a growing emphasis on collaborations and partnerships between academic institutes, biotechnology startups, and established pharmaceutical companies. Various key players engaged in this market have undertaken various initiatives to out-license / in-license several such antibody discovery platforms. For instance, recently, in June 2023, AbTherx entered into an agreement with Gilead Sciences in order to in-license latter’s novel transgenic mouse technology, named Atlas™ Mice. In addition, in January 2023, Hummingbird Bioscience entered into an agreement with Synaffix in order to utilize Synaffix’s proprietary technologies, GlycoConnect™ and HydraSpace™.
Market Size: Key Segments of the Antibody Drug Discovery Services and Platforms Market
The global market size for antibody drug discovery services and platforms is anticipated to grow at an annualized CAGR of 11.0%, during the forecast period, 2023-2035. At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. The hit generation step, which usually employs high-throughput screening and computational methods to accelerate drug discovery, generally accounts for the major proportion of the R&D expenditure in the antibody discovery processes. Given its significance in antibody discovery processes, this trend is unlikely to change during the forecast period. Further, in terms of the antibody discovery method, hybridoma method captures the largest market share (over 30%) of the overall antibody discovery services and platforms market. Owing the capability of hybridoma method to lead the fusion of antibody-producing B cells with myeloma cells in order to create immortalized cell lines capable of continuous antibody manufacturing, this method has proven valuable for generating targeted antibodies for various therapeutic and research applications.
Presently, close to 40% of the market is captured by companies based in North America. Driven by the rising interest in advanced antibody discovery platforms and increasing need for outsourcing in the pharmaceutical industry, the market size for antibody drug discovery services and platforms in North America is anticipated to grow at a CAGR of 12%, during the forecast period, 2023-2035. Several factors contribute to the region’s dominance in this domain, which include the presence of big pharma companies with well-established R&D divisions that foster innovation and drive the demand for advanced antibody discovery platforms.
Examples of key players (which have also been profiled in this market report) engaged in antibody discovery market include (in alphabetical order) Ablexis, Antibody Solutions, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, Myrio Therapeutics, Nona Biosciences, Rockland Immunochemicals, Synbio technologies and WuXi Biologics. This market report includes an easily searchable excel database of all the antibody discovery service providers and antibody discovery platform providers worldwide.
![]() |
![]() |
![]() |
Several recent developments have taken place in the field of antibody discovery in terms of both services and platforms. We’ve outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in antibody discovery services market, across different segments as defined in the below table:
Key Report Attributes | Details | |
Historical Trend |
2017 – 2021 |
|
Base Year |
2022 |
|
Forecast Period |
2023 – 2035 |
|
Market Size 2023 |
$1.6 Billion |
|
CAGR |
12.0% |
|
Type of Service Offered |
|
|
Antibody Discovery Method |
|
|
Type of Antibody Generated |
|
|
Nature of Antibody Generated |
|
|
Type of Therapeutic Area |
|
|
Key Geographical Regions |
|
|
Key Companies Profiled |
(Full list of over 350 companies captured available in the report) |
|
Customization Scope |
15% Free Customization Option |
|
PowerPoint Presentation (Complimentary) |
Available |
|
Excel Data Packs (Complimentary) |
|
The market research report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market report features:
![]() |
![]() |
![]() |
One of the key objectives of the market report was to estimate the current opportunity and future growth potential for antibody discovery services and platforms market over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), type of antibody generated (monoclonal antibodies, bispecific antibodies and others), nature of antibody generated (chimeric, human, humanized and murine), type of therapeutic areas (cardiovascular disorders, immunological disorders, infectious disorders, neurological disorders, oncological disorders and others) and key geographical regions (North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.